Elicio Therapeutics
ELTX
38 hedge funds and large institutions have $4.71M invested in Elicio Therapeutics in 2022 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 9 increasing their positions, 16 reducing their positions, and 8 closing their positions.
0.03% less ownership
Funds ownership: 1.73% → 1.7% (-0.03%)
12% less funds holding
Funds holding: 43 → 38 (-5)
20% less capital invested
Capital invested by funds: $5.9M → $4.71M (-$1.19M)
44% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 16
63% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PWAM
Park West Asset Management
San Francisco,
California
|
+$308K |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$104K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$85.6K |
| 4 |
CM
CM Management
Gulf Breeze,
Florida
|
+$78.4K |
| 5 |
CC
Cannell Capital
Alta,
Wyoming
|
+$35.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LSAG
Lake Street Advisors Group
Portsmouth,
New Hampshire
|
-$282K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$133K |
| 3 |
KCM
Knoll Capital Management
Miami,
Florida
|
-$68K |
| 4 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$67.9K |
| 5 |
Millennium Management
New York
|
-$60.4K |
ELTX Hedge Fund Activity: Q3 2022 in Review
38 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Elicio Therapeutics (ELTX) for Q3 2022, worth a combined $4.71M — down 20% from $5.9M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of ELTX and 3 opened new positions — a net loss of 5 holders — while 16 trimmed existing stakes and 9 added.
The largest buyer was Park West Asset Management, adding an estimated $308K. The largest seller was Lake Street Advisors Group, exiting entirely with an estimated $282K sold.
- 38 institutional investors held Elicio Therapeutics (ELTX) as of Q3 2022, down from 43 in Q2 2022.
- Funds reported $4.71M of Elicio Therapeutics stock for Q3 2022, down 20% quarter-over-quarter.
- 3 funds opened new Elicio Therapeutics positions in Q3 2022 and 8 closed out, a net change of -5 holders.
- The largest Elicio Therapeutics buyer in Q3 2022 was Park West Asset Management, an estimated $308K added.
- The largest Elicio Therapeutics seller in Q3 2022 was Lake Street Advisors Group, an estimated $282K sold.
Based on aggregated 13F filings for Q3 2022.